Investment managers T. Rowe Price and Baillie Gifford led a $200m Series C funding round in DNA Script, a biotechnology company. Additional investors include Healthcor Management, eureKARE, Irving Investors, Coatue Management, Catalio Capital Management, Fidelity Management & Research, Columbia Threadneedle Investments and Casdin Capital. “We are thrilled to partner with this world-class group of investors, including new participants Baillie Gifford and T. Rowe Price, who collectively share our vision to increase access to oligo manufacturing to accelerate the bio-revolution. SYNTAX is the first step toward creating a new paradigm for DNA and RNA synthesis. With the support of our investors, we look forward to continuing to advance this new paradigm to solve some of our largest challenges and advance human health," Thomas Ybert, DNA Script Co-Founder and CEO.